Aurobindo Pharma Ltd Quarterly Results

Q2 FY26-27 Results Summary

Revenue

The revenue stands at ₹10,263.29 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.16 per cent from ₹9,150.35 crore. This corresponds to a year-on-year *(YoY) growth of 23.87 per cent.

Operating Profit

Operating Profit stands at ₹2,152.81 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.04 per cent from ₹1,839.34 crore. This corresponds to a year-on-year *(YoY) growth of 28.29 per cent.

PBDT

PBDT stands at ₹2,218.82 crore, reflecting a quarter-on-quarter *(QoQ) increase of 10.84 per cent from ₹2,001.91 crore. This corresponds to a year-on-year *(YoY) growth of 30.13 per cent.

Profit Before Tax

Profit Before Tax stands at ₹1,687.67 crore, reflecting a quarter-on-quarter *(QoQ) increase of 11.39 per cent from ₹1,515.09 crore. This corresponds to a year-on-year *(YoY) growth of 32.27 per cent.

Net Profit

Net Profit stands at ₹1,123.84 crore, reflecting a quarter-on-quarter *(QoQ) increase of 8.90 per cent from ₹1,032.03 crore. This represents a 32.51 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Aurobindo Pharma Ltd Earnings

CategoryQ2 FY26-27Q2 FY25-26Change %FY25-26FY24-25Change %
Total Revenue10,263.298,285.7023.8733,653.0831,723.736.08
Expenses8,110.486,607.6022.7426,872.6825,172.636.75
Other Income168.22122.2537.60493.61621.85-20.62
Operating Profit2,152.811,678.1028.297,274.017,172.951.41
Depreciation531.15429.1923.761,778.191,649.427.81
Interest102.2195.247.32383.97457.24-16.02
Profit Before Tax1,687.671,275.9232.275,111.855,066.290.90
Tax563.83427.7931.801,736.141,699.982.13
Net Profit1,123.84848.1332.513,502.973,483.570.56
CategoryQ2 FY26-27Q1 FY26-27Change %
Total Revenue10,263.299,150.3512.16
Expenses8,110.487,311.0110.94
Other Income168.22264.23-36.34
Operating Profit2,152.811,839.3417.04
Depreciation531.15486.829.11
Interest102.21101.660.54
Profit Before Tax1,687.671,515.0911.39
Tax563.83483.0616.72
Net Profit1,123.841,032.038.90

Aurobindo Pharma Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Buy 1,610JM Financial23-Mar-2026
Buy 1,430Motilal Oswal04-Dec-2025
Buy 1,460Edelweiss Securities20-Jun-2025
Buy 1,387JM Financial28-May-2025
Buy 1,370Motilal Oswal28-May-2025

Aurobindo Pharma Ltd Financial Reports

Data not available.

Aurobindo Pharma Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Aurobindo Pharma-0.65%0.41%13.90%10.82%16.09%48.95%
Dr Reddy's Labs-0.54%0.76%12.35%18.34%5.47%11.73%
Cipla-0.07%1.50%7.70%-0.79%0.95%-6.38%
Mankind Pharma1.14%1.33%16.62%12.14%5.77%18.59%
Lupin0.55%1.90%2.71%-8.34%-12.05%-0.92%
Glenmark Pharma.1.03%0.73%20.09%14.83%10.82%43.51%
Alkem Lab0.41%0.51%4.05%-4.29%-6.06%-9.39%

Aurobindo Pharma Ltd Corporate Information

Chairman & Independent Directo: M R Kumar
Vice Chairman & M.D.: Kambam Nityananda Reddy
E D & Wholetime Director: M Madan Mohan Reddy
Non Executive Director: P V Ramprasad Reddy
Non-Exec & Non-Independent Dir: Penaka Sarath Chandra Reddy
Independent Non Exe. Director: Girish Paman Vanvari
Independent Non Exe. Director: Santanu Mukherjee
Non-Exec & Non-Independent Dir: Satakarni Makkapati
Independent Non Exe. Director: Punita Kumar Sinha
Company Sec. & Compli. Officer: B Adi Reddy

Aurobindo Pharma Ltd News

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

Updated On: 03 Jul 2026 | 2:57 PM IST

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Updated On: 29 Jun 2026 | 11:21 AM IST

Stocks to Watch today, June 29: Tata Motors PV, Torrent Power, Dr Reddy's Laboratories, Aurobindo Pharma, KEC International, and Adani Ports are among the top stocks to watch during today's trade

Updated On: 29 Jun 2026 | 8:01 AM IST

Market outlook by Ajit Mishra: The analyst from Religare Broking expects Nifty to consolidate in the near-term; among stocks he recommends Delhivery, Ather Energy and Aurobindo Pharma.

Updated On: 25 Jun 2026 | 7:30 AM IST

Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i

Updated On: 22 Jun 2026 | 12:00 PM IST

Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.

Updated On: 19 Jun 2026 | 11:52 AM IST

Stocks to Watch today, May 25, 2026: Shares of oil marketing companies will remain in focus today after petrol and diesel prices were raised by ₹2.61-2.71 per litre on Monday

Updated On: 25 May 2026 | 7:25 AM IST

Aurobindo Pharma Q4 results 2026: Aurobindo Pharma has reported a 2 per cent rise in consolidated profit after tax to ₹920.84 crore in the fourth quarter ended March 31.

Updated On: 22 May 2026 | 2:32 PM IST

Stocks to Watch today, May 22, 2026: Nykaa, LIC, ITC, Honasa Consumer, and Maruti Suzuki are some of the key stocks to watch today

Updated On: 22 May 2026 | 7:54 AM IST

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Updated On: 22 May 2026 | 7:32 AM IST
More